ABCB1 and prostate carcinoma: In another study with doxorubicin-resistant prostate cancer cell lines 0.03 and PC 0.03, the mechanism responsible for resistance development was found to be MRP1 rather than MDR1 (Zalcberg et al., 2000[38]).